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Background: Obstructive sleep apnea (OSA) is associated with an increased prevalence of car-
diovascular diseases. New generations of highly sensitive assays for cardiac troponin (hs-cTnT)
have been introduced recently, and a number of clinical observations have challenged the
notion that troponins are only increased in blood following irreversible necrosis.
Objective: The aims of this study were to compare the levels of hs-cTnT between a group of
healthy controls and a group of patients with OSA without co-existent coronary artery disease,
and to assess the possible influence of the treatment with Continuous positive airway pressure
(CPAP) on these levels.
Methods: The study population included 200 male participants. The case (nZ 133) or control
(n Z 67) status was defined by an apneaehypopnea index of 10 or greater. The hs-cTnT assay
was validated as reported previously, with a limit of detection of 3 ng/L and an upper refer-
ence limit (99th percentile) of 14 ng/L.
Results: The proportion of subjects with detectable plasma hs-cTnTwas higher in patients with
OSA than in controls (61 vs 75%, pZ 0.04). In patients, a significant increase in hs-cTnT levels
was observed after an effective treatment with CPAP (7.3  3.4 vs 10.1  4.9 ng/L; p < 0.01).estigaciones Sanitarias (PI10/02745).
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CPAP treatment and high-sensitivity troponin in OSA. 1061Conclusion: This study shows that the percentage of subjects with detectable hs-cTnT is asso-
ciated with the presence of OSA. It also evidences that treatment with CPAP is followed by a
rise in hs-cTnT concentrations. It is reasonable to suggest that CPAP therapy might induce a
potential degree of cardiac stress, resulting in deleterious consequences for the heart.
ª 2014 Published by Elsevier Ltd.Obstructive sleep apnea (OSA) is associated with an
increased prevalence of cardiovascular diseases [1].
Continuous positive airway pressure (CPAP) treatment re-
duces cardiovascular risk in OSA and recent evidence sug-
gests that early signs of atherosclerosis as well as
endothelial dysfunction and cardiac remodeling are
partially reversed after treatment with CPAP [2e4].
Cardiac troponins (cTnI and cTnT) are components of the
myofibrillar contractile apparatus of cardiomyocytes and
are considered the most sensitive and specific biochemical
markers of myocardial damage [5]. Traditionally, it was
thought that any release of detectable concentrations of
cardiac troponins (cTn) was equivalent to irreversible
myocardial injury. However, new generations of highly
sensitive for cTn (hs-cTn) have been introduced recently
and there have been a number of clinical observations that
have challenged the notion that troponins are only
increased in blood following irreversible necrosis [6,7].
A recent approach demonstrates that hs-cTnT levels
increase in proportion to OSA severity, but in a multivariate
model, OSA was not an independent predictor of hs-cTnT,
suggesting that a clustering of cardiovascular risk factors
explains this association [8]. However, the clinical signifi-
cance and mechanism of the increase in hs-cTnT in patients
with OSA remain unclear. It is unknown whether treatment
of OSA with CPAP would modify the release of cardiac
troponins.
The aim of this study was to assess the possible influence
of the treatment with CPAP on hs-cTnT in a group of pa-
tients with OSA without co-existent coronary artery
disease.
The study population included 200 male participants
recruited from subjects consecutively admitted to the
sleep unit of our institution. The case (n Z 133) or control
(n Z 67) status was defined by the apneaehypopnea index
(AHI) threshold of 10 or greater (case are subjects with an
AHI 10 and controls those with an AHI < 10). Patients with
cardiovascular disease (myocardial infarction, unstable
angina, coronary bypass or coronary angioplasty, stroke or
transient ischemic attack) were excluded. No participant
suffered from any other chronic disease (diabetes, chronic
obstructive pulmonary disease (COPD), liver cirrhosis, thy-
roid dysfunction, chronic renal failure and/or psychiatric
disorders). Participants were recruited from subjects who
attended our sleep unit. We initially excluded participants
(controls or patients) who were taking hypoglycemic,
antihypertensive, hypolipemiant and/or anti-inflammatory
agents.
Patients were studied at diagnosis and after effective
treatment with CPAP (REM Star, Respironics, Murrysville,
PA, USA) during 12 months. Patients with detectable hs-
cTnT levels and who used the device for a minimum of
4 h/night were included in the follow-up analysis (nZ 95).The study was approved by the Ethics Committee of our
institution, and all participants signed their consent after
being fully informed of its goal and characteristics.
The diagnosis of OSA was established by full poly-
somnography (E-Series Compumedics, Abbotsford,
Australia) that included recording of oronasal flow, thor-
acoabdominal movements, electrocardiography, submental
and pretibial electromyography, electrooculography, elec-
troencefalography and trancutaneous measurement of
arterial oxygen saturation. Apnea was defined by the
absence of airflow for more than 10 s. Hypopnea was
defined as any airflow reduction that last more than 10 s
and resulted in arousal or oxygen desaturation. We
considered desaturation a decrease in SaO2 greater than
3%. The apneaehypopnea index (AHI) was defined as the
sum of the number of apneas plus hypopneas per hour of
sleep. Excessive daytime sleepiness (EDS) was quantified
subjectively by the Epworth sleepiness scale (ESS).
After fasting overnight, venous blood samples were ob-
tained between 8 and 10 am. Blood was centrifuged and
serum was immediately separated in aliquots and stored at
80 C until analysis. Glucose, triglycerides, total choles-
terol, HDL cholesterol (HDLc), and creatinine were deter-
mined by standard methods on a Hitachi Modular analyzer
(Roche Diagnostics, Indianapolis, USA). The plasma levels of
hs-cTnT were measured on the Cobas e 411 using the highly
sensitive fifth generation cTnT assay (Roche Diagnostics).
The hs-cTnT was validated as reported previously with the
upper reference limit (99th percentile) at 14 ng/L, limit of
detection at 3 ng/L and 10% coefficient of variation cut-off
at 13 ng/L [9].
Results are presented as percentages, median or
mean  standard deviations. Parametric (Student t test)
and non-parametric test (Wilcoxon test) were performed to
assess the statistical significance of differences between
groups. The effects of CPAP therapy were analyzed using
paired t-tests.
Correlations between variables were explored using the
Spearman-rank test. Separate multiple regression analyses
were used to identify the independent variables associated
with hs-cTnT. A p value lower than 0.05 was considered
significant.
Characteristics of the study population are summarized
in Table 1.
BMI, waist circumference, systolic (SBP) and diastolic
(DBP) pressure were significantly higher in patients with
OSA than in subjects without OSA. Compared to control
subjects, OSA patients showed abnormal plasma levels of
glucose and triglycerides.
The proportion of subjects with detectable hs-cTnT was
higher in patients with OSA than in controls (61 vs 75%,
p Z 0.04). Nevertheless, the levels of hs-cTnT in patients
with detectable hs-cTnT levels were not higher than in
Table 1 Baseline characteristics and sleep profiles in
controls and OSA patients.
Controls
(n Z 67)
OSA
(n Z 133)
Age (years) 48  11 51  9
BMI (kg m2) 26  4 31  6*
Waist circumference (cm) 96  13 110  13*
AHI (h1) 5  2 56  25*
Arousal index (h1) 22  4 59  23*
Mean sat O2 (%) 97  2 94  3*
Minimal sat O2 (%) 90  3 82  3*
Epworth scale 8  2 9  3
SBP (mm Hg) 123  16 134  15*
DBP (mm Hg) 75  10 83  12*
Glucose (mg/dL) 98  17 108  20*
Triglycerides (mg/dL) 119  46 167  74*
Cholesterol (mg/dL) 194  44 207  37
HDLc (mg/dL) 51  12 49  7
Creatinine (mg/dL) 0.89  0.2 0.96  0.3
*p < 0.05.
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6.9  2.3 ng/L, p Z 0.163).
The baseline characteristics of OSA patients with
detectable hs-cTnT levels (75%, n Z 100), were not
different than those with no detectable hs-cTnT (25%,
n Z 33).
hs-cTnT were significantly related to apneaehypopnea
index (rZ 0.165, pZ 0.0132), age (rZ 0.411, p < 0.001),
SBP (rZ 0.290, p < 0.001), DBP (rZ 0.197, pZ 0.008), BMI
(rZ 0.188, pZ 0.010) and waist circumference (rZ 0.330,
p < 0.001). Multivariate analysis showed that the inde-
pendent variables associated with hs-cTnT were age
(p Z 0.018) and BMI (p Z 0.038). A statistically significant
elevation was observed in the levels of hs-cTnT in patients
after CPAP treatment (10.1  4.9 vs 7.3  3.4 ng/L,
p < 0001) (Fig. 1). They also manifested a significant in-
crease in HDLc cholesterol compared to baseline despite
similar BMI. There were no significant changes in waist
circumference, SBP, DBP, glucose and triglyceride levels.Figure 1 Mean values of hs-cTnT at diagnosis and after
treatment with CPAP.This study shows that the percentage of subjects with
detectable cTnT is associated with the presence of OSA. It
also evidences that treatment with CPAP is followed by a
rise in the concentrations of hs-cTnT.
The mechanisms that support a relationship between
OSA and increased hs-cTnT levels are not known. Recent
findings may explain why plasma troponin concentrations
are detected in patients with OSA in absence of myocardial
necrosis. Mechanical stretch of cardiomyocytes due to
increased sympathetic activity and intrathoracic pressure
changes during respiratory events may lead to release of
intact troponins [10,11]. A different approach provides
evidence for a positive relationship between OSA and hs-
cTnT, but the authors conclude that this association is
likely to be caused by a clustering of cardiovascular risk
factors among patients with OSA [8].
In the current study, the relationship between OSA and
hs-cTnT was also attenuated after controlling for age, BMI,
waist circumference and mean arterial pressure suggesting
that the concentration of hs-cTnT may vary in OSA ac-
cording to the degree of obesity and metabolic distur-
bances. Therefore, it is possible that the consequences of
sleep apnea on the release of hs-cTn become apparent in
the presence of co-morbidities such as obesity, hyperten-
sion or metabolic syndrome.
A significant elevation was observed in the levels of hs-
cTnT after CPAP therapy. We observed that this increase
was not dependent on obesity unlike the independent
relationship detected between basal BMI and hs-cTnT. The
underlying mechanisms responsible for CPAP induced
troponin release are unclear.
On the one hand, it is reasonable to suggest that CPAP
therapy has a potential degree of cardiac stress that results
in deleterious consequences for the heart, thus inducing
the release of troponin. By contrast, some recent studies
have demonstrated a progressive improvement in cardio-
vascular remodeling in patients with OSA receiving CPAP
therapy [3,4].
On the other hand, there is increasing evidence of a slow
continuous turnover of cardiomyocytes and minor eleva-
tions of troponin could be a consequence of a cardiac
adaptation to CPAP [12]. Although a direct effect of CPAP
therapy on release of hs-cTnT is questionable, we speculate
that this release could represent a reversible change in
membrane permeability of the cardiomyocyte and reflect
part of a regulatory process of repair leading to enhanced
structure and function. An adaptive response to CPAP,
including fiber regeneration and connective tissue changes
might protect against further cardiac injury. In any case,
quantitative measures of myocardial function and perfusion
would be helpful in elucidating the cellular and physiologic
bases.
Several limitations should be considered. First, despite
patients with diagnosed cardiovascular disease were
excluded, objective measures of myocardial function,
including echocardiographic assessments are necessary to
define standard levels of hs-TnT. Second, hs-cTnT changes
observed in this study might have other potential causes
that are not investigated. It is possible that other physical
and environmental factors have either adverse or favorable
effects on the release of troponin. Third, the lack of
randomization and the absence of data about those
CPAP treatment and high-sensitivity troponin in OSA. 1063patients with undetectable hs-TnT levels before CPAP
starting limited our study. Follow up of patients under CPAP
including serial measurements of hs-cTnT is necessary to
determine the mechanisms responsible for the release of
troponin in patients with OSA and their clinical significance.
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